Elvie, the London-based femtech company that made pelvic floor health and wearable breast pumps mainstream, entered administration in March 2025 — a stunning fall for a company that had raised over $186 million from investors including Octopus Ventures, BlackRock, and Blume Equity over 12 years.

Why It Matters

Elvie's fall is a cautionary tale for the femtech sector: even with $186M in funding, category-defining products, and genuine cultural impact, premium hardware companies targeting women's health can fail if they cannot solve the unit economics equation. The Willow acquisition consolidates market power in wearable breast pumps, which could affect pricing and innovation for consumers.

US competitor Willow, a San Francisco breast pump startup, acquired Elvie's assets including its technology, branding, intellectual property, and team. The acquisition also resolved a pending patent lawsuit that Willow had filed against Elvie. Deal terms were not publicly disclosed.

Elvie's collapse was driven by multiple converging factors: a premium pricing strategy (the Elvie double Pump retailed at over $600) that became untenable during the cost-of-living crisis, a costly direct-to-consumer sales model, and investor pressure to scale too fast. The company had expanded its product line from the original Elvie Trainer (pelvic floor) to the Elvie Pump and eventually a bassinet — spreading resources thin.

The failure carries symbolic weight for the femtech sector. Elvie was a category creator that normalized conversations about pelvic floor health, breastfeeding, and postpartum recovery. Its demise suggests that even groundbreaking products need sustainable unit economics to survive.

Willow's acquisition positions it as the dominant player in wearable breast pumps, consolidating two of the category's three main competitors. The combined company holds significant IP across pump technology, pelvic health sensors, and maternal wellness.

Sources

Update — 2026-03-14

Initial entry — story first created.